J. D. Bono

发表

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

N. Agarwal, A. Kohlmann, O. Sartor, 2019, Annals of Oncology.

Analysis of DNA methylation in single circulating tumor cells

T. Fehm, J. Bono, W. Schulz, 2017, Oncogene.

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

N. Agarwal, C. Corcoran, O. Sartor, 2020, Annals of Oncology.

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

C. Sternberg, M. Borre, M. Wongchenko, 2020 .

576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

K. Rahbar, M. Morris, B. Krause, 2021, Annals of Oncology.

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

A. Kohlmann, C. Gedye, C. Corcoran, 2019, Annals of Oncology.

Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers

U. Banerji, T. Yap, P. Flohr, 2016 .

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

P. Kantoff, H. Scher, D. Rathkopf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A decade of clinical development of PARP inhibitors in perspective

A. Tutt, J. Bono, C. Lord, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

B. Tombal, S. Oudard, G. Gravis, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

J. Bono, L. Terstappen, R. Ferraldeschi, 2015, British Journal of Cancer.

Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer.

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

H. Wu, N. Tunariu, J. Bono, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. Parmar, M. Sydes, D. Dearnaley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

F. Mottaghy, S. Lheureux, P. Ohashi, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

D. Dearnaley, C. Parker, J. Bono, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

R. Plummer, S. Crabb, L. Carter, 2021, Annals of Oncology.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

J. Luo, Jun Luo, N. Tunariu, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.